• Boston Scientific reported fourth-quarter and full-year 2025 results on February 4, 2026, delivering higher sales and net income, while also issuing 2026 guidance that called for reported net sales growth of about 10.5% to 11.5% and organic growth of about 10.0% to 11.0%.
• At the same time, investors learned that growth in important electrophysiology and WATCHMAN heart device franchises had flattened sequentially, even as the company continued to invest heavily in innovation and acquisitions such as Penumbra and Valencia Technologies.
• We’ll now examine how Boston Scientific’s strong 2025 performance but more cautious 2026 outlook for electrophysiology and WATCHMAN shapes its investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is Boston Scientific's Investment Narrative?

For Boston Scientific, the core belief is that a diversified cardiovascular and MedSurg portfolio, backed by consistent double‑digit revenue and earnings growth in 2025, can justify a premium valuation even after a sharp share price pullback. The recent selloff, triggered by flattening electrophysiology and WATCHMAN trends and a 2026 guide that reset expectations, puts the focus squarely on whether these franchises can reaccelerate and whether new launches and acquisitions like Penumbra and Valencia can offset any soft spots. Near term, the CHAMPION‑AF data and integration of recent deals remain the key swing factors, while higher leverage and a rich earnings multiple are the pressure points if growth or execution wobbles. The planned board refresh, including Yoshiaki Fujimori’s upcoming departure, looks incremental rather than thesis‑changing.

However, the premium valuation makes any stumble in EP or WATCHMAN growth more painful for shareholders. Despite retreating, Boston Scientific's shares might still be trading 7% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

Seven Simply Wall St Community fair value views cluster between about US$83.79 and US$110, underlining how widely expectations differ. You are weighing these against near term EP and WATCHMAN uncertainties that could influence how quickly recent share price weakness stabilizes or extends.

Explore 7 other fair value estimates on Boston Scientific - why the stock might be worth just $83.79!

Build Your Own Boston Scientific Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Boston Scientific research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Boston Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Boston Scientific's overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The latest GPUs need a type of rare earth metal called Neodymium and there are only 31 companies in the world exploring or producing it. Find the list for free.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• Find 55 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.